BeiGene said Antaishi (tarlatamab injection), the first and currently only DLL3×CD3 bispecific T‑cell engager co‑developed and to be commercialized with Amgen, received approval from China’s National Medical Products Administration (NMPA) for adults with extensive‑stage small‑cell lung cancer (ES‑SCLC) who progressed after one prior systemic therapy, including platinum‑based chemotherapy.

Guangzhou’s 15th Five-Year Plan prioritizes expanding the semiconductor and integrated circuit sector, targeting breakthroughs in specialty-process chip manufacturing, automotive-grade chip design, advanced packaging and third-generation semiconductors. The plan aims to establish a new high-end digital chip track and position Guangzhou as a national integrated circuit industry “third pole” core base. It calls for accelerating major projects including Yuexin Phase IV, backing Huangpu to attract high-end chip design, critical materials and equipment suppliers, and advanced packaging/testing firms to develop an analog chip supply chain; supporting Zengcheng to focus on intelligent sensors and specialty-process chip manufacturing; and supporting Nansha to build a wide-bandgap semiconductor industry cluster.

Spain May harmonized CPI (HICP) preliminary MoM +0.1% vs expected +0.2%; April +0.70%.